NGM 282

Drug Profile

NGM 282

Alternative Names: NGM-282

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator NGM Biopharmaceuticals
  • Class Antihyperglycaemics
  • Mechanism of Action Cholesterol 7 alpha hydroxylase inhibitors; Fibroblast growth factor receptor modulators; Type 1 fibroblast growth factor receptor modulators; Type 4 fibroblast growth factor receptor modulators; Type-2 fibroblast growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary biliary cirrhosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Primary biliary cirrhosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis; Type 2 diabetes mellitus
  • Phase I/II Constipation

Most Recent Events

  • 01 Jan 2017 NGM Biopharmaceuticals completes a phase I/II trial in Constipation in USA (Parenteral) (NCT02649062)
  • 01 Feb 2016 Phase-II clinical trials in Primary sclerosing cholangitis in USA (Parenteral) (NCT02704364)
  • 01 Dec 2015 Phase-I/II clinical trials in Constipation in USA (Parenteral) (NCT02649062)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top